Profiles

Nuri Guven

UTAS Home Associate Professor Nuri Güven

Nuri Güven

Associate Professor of Pharmaceutical Science, Graduate Research Coordinator (Pharmacy)

Room 2032, Chemistry Building, Sandy Bay Campus

+61 3 6226 1715 (phone)

+61 3 6226 2870 (fax)

Nuri.Guven@utas.edu.au

Humans, like every other living organism, are made of cells that need energy to survive. Within each human cell are organelles known as mitochondria. Tiny they may be, yet mitochondria produce more than 90 per cent of all the energy our bodies need to function. And so, it’s not surprising that dysfunctional mitochondria are associated with a large number of diseases, from neurodegenerative Alzheimer’s, Parkinson’s and Huntington’s to inflammatory conditions such as inflammatory bowel disease (IBD). Metabolic disorders such as diabetes, and even cancer, can occur when the mitochondria don’t function as they should. As people age, they become more prone to diseases because the mitochondria work less efficiently.

Despite this, at the moment there is just one drug on the market that has a small effect on dysfunctional mitochondria. It is only available in Europe. And, it’s only approved for a single disease so rare that it affects one in 50,000 people…

In contrast, millions of patients worldwide suffer from disorders that show mitochondrial problems, with insufficient treatment options and an astronomical impact on our healthcare systems. For example, by 2023, the global market for ulcerative colitis, a form of IBD, is estimated to reach 7.5 billion. The market for diabetes-induced vision loss, also called diabetic retinopathy, is expected to reach 10 billion by 2025.

Could the microscopic organelles that power our bodies lead us to discover game-changing new drugs?

Associate Professor Nuri Guven is an expert in drug discovery and development. His research is focused on identifying and developing new molecules to protect against mitochondrial dysfunction in order to develop novel drug candidates.

‘What we’re striving for is to identify molecules that can be used in a whole range of diseases,’ explains Associate Professor Guven. ‘Our aim is to restore mitochondrial function in different tissues, which could enable us to combat a wide range of disorders.

‘We have some very interesting molecules and some very encouraging pre-clinical data. In fact, at least in the lab, we can protect the survival of cells when the mitochondria are impaired or dysfunctional.

‘This is so exciting, but we still have to be very careful,’ warns Associate Professor Guven. ‘Lots of drug candidates show promise in the pre-clinical testing stage, but less than one in a hundred ends up working in humans to a reasonable degree.

‘When the first really efficient drug comes to market it really will be a game-changer, because it is likely to be beneficial for a whole range of disorders, not just one.’

Associate Professor Guven collaborates with Associate Professor Smith from the School of Natural Sciences and many other researchers across the College of Health and Medicine.

‘After the chemists make new molecules, we first of all test their activity,’ he explains. ‘When designing drugs, our main questions are do they work, and are they toxic? I test the efficacy and the toxicity, and the results are then used for the design of the next molecules. That way, we try to make the compound better and better over several stages. This is what’s called the Medicinal Chemistry Program.’

During previous biomedical research, Associate Professor Guven liaised with many patients, which was the inspiration for his career. ‘When you’re speaking to someone with a rare disease and there are no drugs available to them… well, it brings home the good that comes from biomedical research,’ he says.

‘I realised that if I wanted to do anything about it, I had to move away from basic research and into drug discovery. Some of these classic mitochondrial diseases are so rare that the chance of a company developing an effective drug to combat them is negligible.

‘If we can find a drug that works in one of the larger diseases, once it’s on the market, doctors can potentially prescribe it to patients suffering from rare indications. This is a realistic scenario. The “repurposing” of drugs is an effective way of treating patients suffering from diseases for which there are no available drugs at this stage,’ says Associate Professor Guven.

‘It’s a very long process. We could have the best drug in the world, but if it’s not patented and our research isn’t funded, it won’t make it to market. At the end of the day, I want to see drugs reach the market and help patients.’

Assoc Prof Gueven is a biochemist with many years experience in pre-clinical, drug-related research using cell-free, cell culture and animal models of human disease. He has worked on cancer and neurodegenerative disorders and has recently turned his interest to mitochondrial dysfunction, which is inherent to a large number of major disorders ranging from cancer to glaucoma. He is testing known compounds, novel extracts but also collaborates with different Australian chemists to develop and test novel drug candidates. His interest lies not only in scientific discovery but also in research that eventually can find its way to patients. Therefore his current research is mainly funded by patient charities as well as commercial sources.

Biography

Assoc Prof Gueven joined UTAS in April 2012, where he acted as Deputy Head (School of Pharmacy) and then Associate Deputy Head (School of Medicine, Division of Pharmacy). Previously he directed the pre-clinical research department at Santhera Pharmaceuticals (Liestal, Switzerland, 2008-2012), where he led several drug discovery projects around novel treatments for neuromuscular disorders and in the field of cancer cachexia. From 2001-2008 he was Senior Research Officer at the Queensland Institute of Medical Research (QIMR, Brisbane, Australia), in the DNA damage and repair field, where he specialized in recessive ataxia syndromes, p53, oxidative stress-induced malignancy and animal models. During this time he was chief investigator on 2 NHMRC and 2 Queensland Cancer Fund applications and attracted US funding for his pharmaceutical work in a cancer mouse model as CIA. He worked on an industry-project at the University of Tübingen (Department of Radiationoncology, Germany 1999-2002) to identify the active component of a radioprotective drug. His PhD was awarded in 1998 from the University of Konstanz (Germany) in the area of drug discovery in radiation-oncology.

Career summary

Qualifications

  • PhD, University of Konstanz and University of Tübingen, Germany. 1998
  • Masters, University of Konstanz, Germany. 2003

Languages (other than English)

German

Memberships

Professional practice

  • NIH DNA Repair Special Interest Group
  • Associate Investigator of the Australian Research Council (ARC) Centre of Excellence for Free Radical Chemistry and Biotechnology
  • Member of the scientific research advisory committee of the Royal Hobart Hospital Research Foundations (RHHRF) and the Erica Bell Foundation
  • Editorial Board Member: PLOS ONE and J Pharmaceutics & Pharmacology

Administrative expertise

Nuri has previously managed multiple drug discovery projects in academic and commercial settings. In these roles he was responsible for line management of multidisciplinary teams (i.e. screening, PK/PD, ADME, cell biology, in vivo models, molecular biology, exploratory, in and out-licencing). In addition he generated documents and presentations for regulatory bodies (EMA/FDA) incl. the participation in interviews and membership on a drug safety committee. Currently he manages several research projects around drug discovery and toxicity for multiple indications. He also established lab infrastructure from scratch in several academic and commercial institutions (layout, equipment acquisition, lab maintenance, SOP generation, budget control) and has a keen interest and experience to protect scientific discoveries by patent applications.

Nuri has held the following administrative positions:

  • Acting Deputy Head of School (Pharmacy, 2012-2013)
  • Acting Deputy Associate Head (Division of Pharmacy, since 2014)
  • Member of the Faculty of Health Sciences Research Committee (2012-2013)
  • School of Medicine Research Committee (since 2014)
  • UTAS Medical Science Precinct (includes the Menzies Institute for Medical Research) Lab Management Team
  • Established and manages the Pharmacy division's cell culture facility

Teaching

Drug discovery and development, toxicology, pre-clinical research, food-supplements, how to give a presentation

Teaching responsibility

Nuri is involved in the organisation and lectures in a number of units within the School of Medicine:

Research Appointments

  • Scientific consultant to Santhera Pharmaceuticals (2012 - present)
  • Scientific advisory committee Erica Bell Foundation
  • Academic Editor: PLOS ONE
  • Academic Editor: J Pharmaceutics & Pharmacology
  • Additional recent review activity for: NHMRC, Australia; ORIA, Australia; AFM, France, Medical Research Charities Group (MRCG), Ireland; Health Research Board (HRB), Ireland; Action Research, UK

View more on Dr Nuri Guven in WARP

Expertise

Assoc Prof Gueven is a biomedical scientist with an international reputation for drug discovery and development in disorders associated with oxidative stress, energy impairment and malignancies. His current interests lie in drug discovery in the areas of ulcerative colitis, colorectal cancer and metabolic disorders. The collective impact of his contribution is highlighted by numerous worldwide collaborations with clinicians and researchers, invitations to speak at international meetings, invited reviews, patents as well as editorial and refereeing work. He gave the keynote lecture at the Muscular Dystrophy Association of New Zealand (MDA) and Australasian Neuromuscular Network (ANN) Conference 2015 and was also the invited speaker at a specialized Workshop on CoQ10 deficiency disorders and therapy (Naarden, Netherlands 2010). Nuri has also presented his work at more general conferences such as ComBio. The relevance of his applied research to the health of patients is demonstrated by two patent disclosures in 2012, and a novel submitted patent application in 2014 in the field of personalized medicine (undisclosed). He has published in prestigious journals (J Cell Biol, Hum Mol Gen, Cell Death Diff). His work is widely cited (a total of more than 1600 citations) with an average of more than 30 citations/paper and more than 450 citations for the most highly cited paper.

Research Themes

Nuri's work aligns with the University Theme: 'Better Health'. His core expertise is pre-clinical drug discovery in the area of mitochondrial and metabolic disorders, inflammatory bowel disease as well as cancer. His research spans several disease areas from cancer to neurodegeneration and metabolism.

http://www.utas.edu.au/health/research/groups/drug-discovery-group

Collaboration

Assoc Prof Gueven is collaborating with scientists and clinicians worldwide. He has numerous active collaborations in the areas of mitochondrial and neuromuscular disorders and is involved in clinical research around a novel treatment for Duchenne Muscular Dystrophy at the Children's Hospital in Basel (Switzerland). He is also collaborating within the University of Tasmania with Dr. Patel (School of Medicine) and Dr. Eri (School of Health Sciences) on the activity of polysaccharides in inflammatory bowel diseases, with Assoc Prof Foa and Dr. Gasperini (School of Medicine) on drug toxicity measurement in zebrafish, with Dr. Smith (School of Chemistry) on the development of novel short chain quinones for the treatment of mitochondrial dysfunction, with Dr. Hewitt and Dr. Cook (School of Medicine) on the use of iPS derived GRC cells in drug screening approaches, just to name a few. In addition, he also collaborates with commercial entities such as Marinova Pty (Cambridge, TAS, Australia) to evaluate their products in various pre-clinical models of disease.

Awards

  • Kevin Cahill Award (2015) for the most interesting or innovative research in the field of Vision Sciences

Current projects

  • Optic neuropathy due to mitochondrial dysfunction in D. rerio (zebrafish) (current)
  • Characterization of DNA damage response of anti-trypanosome compounds (current)
  • Development of short chain quinones for the treatment of mitochondrial disorders (current)
  • Identification of drugs that affect mitochondrial function (current)
  • Fucoidan for the treatment of inflammatory bowel disease (current)
  • Small molecular weight heparins (SMWH) as anti-inflammatory agents (current)

Fields of Research

  • Pharmaceutical Sciences (111504)
  • Signal Transduction (060111)
  • Pharmacology and Pharmaceutical Sciences (111599)
  • Basic Pharmacology (111501)
  • Clinical Pharmacology and Therapeutics (111502)
  • Neurology and Neuromuscular Diseases (110904)
  • Biologically Active Molecules (030401)
  • Ophthalmology (111301)
  • Gastroenterology and Hepatology (110307)
  • Biochemistry and Cell Biology (060199)
  • Organic Chemical Synthesis (030503)
  • Separation Science (030108)
  • Central Nervous System (110903)
  • Cell Development, Proliferation and Death (060103)
  • Medicinal and Biomolecular Chemistry (030499)
  • Clinical Sciences (110399)
  • Medical Biochemistry and Metabolomics (110199)
  • Sensory Systems (110906)
  • Systems Physiology (111603)
  • Animal Physiology - Systems (060603)
  • Proteins and Peptides (030406)
  • Cellular Nervous System (110902)
  • Genetic Immunology (060406)
  • Medical Biochemistry: Proteins and Peptides (incl. Medical Proteomics) (110106)
  • Motor Control (110603)
  • Allergy (110701)
  • Analytical Chemistry (030199)
  • Analytical Biochemistry (060101)
  • Metabolic Medicine (110107)
  • Neurosciences (110999)
  • Animal Cell and Molecular Biology (060802)
  • Medical and Health Sciences (119999)
  • Gene and Molecular Therapy (100401)
  • Complementary and Alternative Medicine (110499)
  • Enzymes (060107)
  • Cell Neurochemistry (060105)
  • Autonomic Nervous System (110901)
  • Optometry and Ophthalmology (111399)
  • Optical Technology (111302)
  • Aquaculture (070401)
  • Peripheral Nervous System (110905)
  • Cellular Immunology (110704)
  • Biological Psychology (Neuropsychology, Psychopharmacology, Physiological Psychology) (170101)
  • Traditional Chinese Medicine and Treatments (110404)
  • Pharmacogenomics (111505)
  • Cell Physiology (111601)
  • Animal Physiology - Cell (060602)
  • Tumour Immunology (110709)
  • Immunology (110799)
  • Epigenetics (incl. Genome Methylation and Epigenomics) (060404)
  • Cell Metabolism (060104)

Research Objectives

  • Expanding Knowledge in the Biological Sciences (970106)
  • Expanding Knowledge in the Medical and Health Sciences (970111)
  • Digestive System Disorders (920105)
  • Nervous System and Disorders (920111)
  • Health (929999)
  • Neurodegenerative Disorders Related to Ageing (920112)
  • Hearing, Vision, Speech and Their Disorders (920107)
  • Cancer and Related Disorders (920102)
  • Human Pharmaceutical Products (860899)
  • Public Health (excl. Specific Population Health) (920499)
  • Diabetes (920104)
  • Expanding Knowledge in the Chemical Sciences (970103)
  • Immune System and Allergy (920108)
  • Human Pharmaceutical Treatments (e.g. Antibiotics) (860803)
  • Clinical Health (Organs, Diseases and Abnormal Conditions) (920199)
  • Inherited Diseases (incl. Gene Therapy) (920110)
  • Preventive Medicine (920412)
  • Respiratory System and Diseases (incl. Asthma) (920115)
  • Behaviour and Health (920401)
  • Skin and Related Disorders (920117)
  • Fisheries - Aquaculture (830199)
  • Cardiovascular System and Diseases (920103)
  • Aboriginal and Torres Strait Islander Health - Determinants of Health (920301)

Publications

Assoc Prof Guven is widely published with about 50% of publications as first or last author and 3 invited reviews. On average Nuri has published 4.4 papers per year over the last 5 years (excluding patents). Nuri's publications are highly cited (>2000) with a H-factor of 20 and the highest cited paper receiving more than 450 citations. Nuri delivered a seminal paper on the activation of the tumour suppressor p53 in Cell Death and Differentiation and was author on the first paper describing molecular activity of short chain quinones that make them useful to treat mitochondrial disease. Nuri is on two international patents disclosed in 2012 from his work in the pharmaceutical industry, which are now part of the essential IP portfolio of the company. One Australian provisional patent application (2014904633 submitted in 2014) with ongoing licence negotiations.

Total publications

80

Journal Article

(62 outputs)
YearCitationAltmetrics
2019Corban M, Ambrose M, Pagnon J, Stringer D, Karpiniec S, et al., 'Pathway analysis of fucoidan activity using a yeast gene deletion library screen', Marine drugs, 17, (1) pp. 1-15. ISSN 1660-3397 (2019) [Refereed Article]

DOI: 10.3390/md17010054 [eCite] [Details]

Citations: Scopus - 1Web of Science - 1

Co-authors: Corban M; Ambrose M; Eri R; Fitton JH

Tweet

2019Hafner P, Bonati U, Klein A, Rubino D, Gocheva V, et al., 'Effect of Combination L-Citrulline and Metformin Treatment on Motor Function in Patients With Duchenne Muscular Dystrophy: A Randomized Clinical Trial', JAMA Network Open, 2, (10) Article e1914171. ISSN 2574-3805 (2019) [Refereed Article]

DOI: 10.1001/jamanetworkopen.2019.14171 [eCite] [Details]

Tweet

2019Woolley KL, Nadikudi M, Koupaei MN, Corban M, McCartney P, et al., 'Amide linked redox-active naphthoquinones for the treatment of mitochondrial dysfunction', MedChemComm, 10, (3) pp. 399-412. ISSN 2040-2511 (2019) [Refereed Article]

DOI: 10.1039/c8md00582f [eCite] [Details]

Citations: Scopus - 1Web of Science - 1

Co-authors: Woolley KL; Nadikudi M; Corban M; Bissember AC; Lewis TW; Smith JA

Tweet

2019Wilson RR, Gundamaraju R, Vemuri R, Angelucci C, Geraghty DP, et al., 'Identification of key pro-survival proteins in isolated colonic goblet cells of Winnie, a murine model of spontaneous colitis', Inflammatory Bowel Diseases pp. 1-13. ISSN 1536-4844 (2019) [Refereed Article]

DOI: 10.1093/ibd/izz179 [eCite] [Details]

Citations: Web of Science - 3

Co-authors: Wilson RR; Vemuri R; Angelucci C; Geraghty DP; Eri RD

Tweet

2018Paul AK, Gueven N, Dietis N, 'Data on prolonged morphine-induced antinociception and behavioral inhibition in older rats', Data in Brief, 19 pp. 183-188. ISSN 2352-3409 (2018) [Refereed Article]

DOI: 10.1016/j.dib.2018.05.001 [eCite] [Details]

Co-authors: Dietis N

Tweet

2018Wanandy T, Wilson R, Gell D, Rose HE, Gueven N, et al., 'Towards complete identification of allergens in Jack Jumper (Myrmecia pilosula) ant venom and their clinical relevance: An immunoproteomic approach', Clinical and Experimental Allergy, 48, (9) pp. 1222-1234. ISSN 1365-2222 (2018) [Refereed Article]

DOI: 10.1111/cea.13224 [eCite] [Details]

Citations: Scopus - 2Web of Science - 2

Co-authors: Wilson R; Gell D; Davies NW; Brown SGA

Tweet

2018Chhetri J, King AE, Gueven N, 'Alzheimer's Disease and NQO1: is there a link?', Current Alzheimer Research, 15 pp. 56-66. ISSN 1567-2050 (2018) [Refereed Article]

DOI: 10.2174/1567205014666170203095802 [eCite] [Details]

Citations: Scopus - 11Web of Science - 9

Co-authors: Chhetri J; King AE

Tweet

2018Paul AK, Gueven N, Dietis N, 'Age-dependent antinociception and behavioral inhibition by morphine', Pharmacology, Biochemistry and Behavior, 168 pp. 8-16. ISSN 0091-3057 (2018) [Refereed Article]

DOI: 10.1016/j.pbb.2018.03.003 [eCite] [Details]

Citations: Scopus - 1Web of Science - 2

Co-authors: Dietis N

Tweet

2017Cui H, Zhang AJ, McKeage MJ, Nott LM, Geraghty D, et al., 'Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity', Journal of Inorganic Biochemistry, 177 pp. 249-258. ISSN 0162-0134 (2017) [Refereed Article]

DOI: 10.1016/j.jinorgbio.2017.04.022 [eCite] [Details]

Citations: Scopus - 4Web of Science - 5

Co-authors: Cui H; Nott LM; Geraghty D

Tweet

2017Deans BJ, Just J, Chhetri J, Burt LK, Smith JN, et al., 'Pressurized hot water extraction as a viable bioprospecting tool: isolation of coumarin natural products from previously unexamined Correa (Rutaceae) species', ChemistrySelect, 2, (8) pp. 2439-2443. ISSN 2365-6549 (2017) [Refereed Article]

DOI: 10.1002/slct.201602006 [eCite] [Details]

Citations: Scopus - 8Web of Science - 8

Co-authors: Deans BJ; Just J; Chhetri J; Burt LK; Smith JN; Kilah NL; Bissember AC; Smith JA

Tweet

2017Gueven N, Nadikudi M, Daniel AO, Chhetri J, 'Targeting mitochondrial function to treat optic neuropathy', Mitochondrion, 36 pp. 7-14. ISSN 1567-7249 (2017) [Refereed Article]

DOI: 10.1016/j.mito.2016.07.013 [eCite] [Details]

Citations: Scopus - 17Web of Science - 11

Co-authors: Nadikudi M; Daniel AO; Chhetri J

Tweet

2017Kunde DA, Chong WC, Nerurkar PV, Ahuja KDK, Just J, et al., 'Bitter melon protects against ER stress in LS174T colonic epithelial cells', BMC Alternative Medicine, 17 Article 2. ISSN 1472-6882 (2017) [Refereed Article]

DOI: 10.1186/s12906-016-1522-1 [eCite] [Details]

Citations: Scopus - 5Web of Science - 5

Co-authors: Kunde DA; Chong WC; Ahuja KDK; Just J; Smith JA; Eri RD

Tweet

2017Paul AK, Guven N, Dietis N, 'Morphine dosing strategy plays a key role in the generation and duration of the produced antinociceptive tolerance', Neuropharmacology, 121 pp. 158-166. ISSN 0028-3908 (2017) [Refereed Article]

DOI: 10.1016/j.neuropharm.2017.04.034 [eCite] [Details]

Citations: Scopus - 3Web of Science - 3

Co-authors: Dietis N

Tweet

2017Alhusban A, Breadmore MC, Gueven N, Guijt RM, 'Time-Resolved Pharmacological Studies using Automated, Online Monitoring of Five Parallel Suspension Cultures', Scientific Reports, 7 pp. 1-9. ISSN 2045-2322 (2017) [Refereed Article]

DOI: 10.1038/s41598-017-10472-1 [eCite] [Details]

Citations: Scopus - 1Web of Science - 1

Co-authors: Breadmore MC; Guijt RM

Tweet

2017Wanandy T, Dwyer HE, McLean L, Davies NW, Nichols D, et al., 'Factors influencing the quality of Myrmecia pilosula (Jack Jumper) ant venom for use in in vitro and in vivo diagnosis of allergen sensitization and in allergen immunotherapy', Clinical and Experimental Allergy, 47, (11) pp. 1478-1490. ISSN 1365-2222 (2017) [Refereed Article]

DOI: 10.1111/cea.12987 [eCite] [Details]

Citations: Scopus - 3Web of Science - 3

Co-authors: Wanandy T; Dwyer HE; McLean L; Davies NW; Nichols D; Brown SGA; Wiese MD

Tweet

2016Alhusban AA, Breadmore MC, Gueven N, Guijt RM, 'Capillary electrophoresis for automated on-line monitoring of suspension cultures: Correlating cell density, nutrients and metabolites in near real-time', Analytica Chimica Acta, 920 pp. 94-101. ISSN 0003-2670 (2016) [Refereed Article]

DOI: 10.1016/j.aca.2016.03.034 [eCite] [Details]

Citations: Scopus - 6Web of Science - 5

Co-authors: Breadmore MC; Guijt RM

Tweet

2016Chhetri J, Gueven N, 'Targeting mitochondrial function to protect against vision loss', Expert Opinion on Emerging Therapeutic Targets, 20, (6) pp. 721-36. ISSN 1472-8222 (2016) [Refereed Article]

DOI: 10.1517/14728222.2015.1134489 [eCite] [Details]

Citations: Scopus - 7Web of Science - 4

Co-authors: Chhetri J

Tweet

2016Gueven N, 'Idebenone for Leber's hereditary optic neuropathy', Drugs of today, 52, (3) pp. 173-181. ISSN 1699-3993 (2016) [Refereed Article]

DOI: 10.1358/dot.2016.52.3.2463564 [eCite] [Details]

Citations: Scopus - 15Web of Science - 9

Tweet

2016Hafner P, Bonati U, Erne B, Schmid M, Rubino D, et al., 'Improved muscle function in Duchenne muscular dystrophy through L-arginine and metformin: an investigator-initiated, open-label, single-center, proof-of-concept-study', PLoS One, 11, (1) Article e0147634. ISSN 1932-6203 (2016) [Refereed Article]

DOI: 10.1371/journal.pone.0147634 [eCite] [Details]

Citations: Scopus - 22Web of Science - 20

Tweet

2016Hafner P, Bonati U, Rubino D, Gocheva V, Zumbrunn T, et al., 'Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial', Trials, 17, (1) Article 389. ISSN 1745-6215 (2016) [Refereed Article]

DOI: 10.1186/s13063-016-1503-1 [eCite] [Details]

Citations: Scopus - 15Web of Science - 14

Tweet

2016Randall-Demllo S, Fernando R, Brain T, Sohal SS, Cook AL, et al., 'Characterisation of colonic dysplasia-like epithelial atypia in murine colitis', World Journal of Gastroenterology, 22, (37) pp. 8334-8348. ISSN 1007-9327 (2016) [Refereed Article]

DOI: 10.3748/wjg.v22.i37.8334 [eCite] [Details]

Citations: Scopus - 6Web of Science - 6

Co-authors: Randall-Demllo S; Sohal SS; Cook AL; Kunde D; Eri R

Tweet

2016Yin X, Guven N, Dietis N, 'Stress-based animal models of depression: Do we actually know what we are doing?', Brain research, 1652 pp. 30-42. ISSN 0006-8993 (2016) [Refereed Article]

DOI: 10.1016/j.brainres.2016.09.027 [eCite] [Details]

Citations: Scopus - 31Web of Science - 27

Co-authors: Yin X; Dietis N

Tweet

2015Buyse GM, Gueven N, McDonald CM, 'Idebenone as a novel therapeutic approach for Duchenne Muscular Dystrophy', European Neurological Review, 10, (2) pp. 189-94. ISSN 1758-3837 (2015) [Refereed Article]

DOI: 10.17925/ENR.2015.10.02.189 [eCite] [Details]

Citations: Scopus - 2

Tweet

2015Guven N, Woolley K, Smith J, 'Border between natural product and drug: comparison of the related benzoquinones idebenone and coenzyme Q10', Redox Biology, 4 pp. 289-295. ISSN 2213-2317 (2015) [Refereed Article]

DOI: 10.1016/j.redox.2015.01.009 [eCite] [Details]

Citations: Scopus - 38Web of Science - 35

Co-authors: Woolley K; Smith J

Tweet

2015Kijas AW, Lim YC, Bolderson E, Cerosaletti K, Gatei M, et al., 'ATM-dependent phosphorylation of MRE11 controls extent of resection during homology directed repair by signalling through Exonuclease 1', Nucleic Acids Research, 43, (17) pp. 8352-8367. ISSN 0305-1048 (2015) [Refereed Article]

DOI: 10.1093/nar/gkv754 [eCite] [Details]

Citations: Scopus - 17Web of Science - 16

Tweet

2015Lean QY, Eri RD, Fitton JH, Patel RP, Gueven N, 'Fucoidan extracts ameliorate acute colitis', PLoS One, 10, (6) Article e0128453. ISSN 1932-6203 (2015) [Refereed Article]

DOI: 10.1371/journal.pone.0128453 [eCite] [Details]

Citations: Scopus - 25Web of Science - 23

Co-authors: Lean QY; Eri RD; Patel RP

Tweet

2015Lean QY, Eri RD, Randall-Demllo S, Sohal SS, Stewart N, et al., 'Orally Administered Enoxaparin Ameliorates Acute Colitis by Reducing Macrophage-Associated Inflammatory Responses', PLoS One, 10, (7) Article e0134259. ISSN 1932-6203 (2015) [Refereed Article]

DOI: 10.1371/journal.pone.0134259 [eCite] [Details]

Citations: Scopus - 11Web of Science - 10

Co-authors: Lean QY; Eri RD; Randall-Demllo S; Sohal SS; Stewart N; Peterson GM; Patel RP

Tweet

2015Lean QY, Gueven N, Eri RD, Bhatia R, Sohal SS, et al., 'Heparins in ulcerative colitis: proposed and potential reasons for inconsistent clinical outcomes', Expert Review of Clinical Pharmacology, 8, (6) pp. 795-811. ISSN 1751-2433 (2015) [Refereed Article]

DOI: 10.1586/17512433.2015.1082425 [eCite] [Details]

Citations: Scopus - 5Web of Science - 4

Co-authors: Lean QY; Eri RD; Sohal SS; Stewart N; Peterson GM; Patel RP

Tweet

2015Shastri MD, Stewart N, Eapen M, Peterson GM, Zaidi STR, et al., 'Opposing effects of low molecular weight heparins on the release of inflammatory cytokines from peripheral blood mononuclear cells of asthmatics', PLoS One, 10, (3) Article e0118798. ISSN 1932-6203 (2015) [Refereed Article]

DOI: 10.1371/journal.pone.0118798 [eCite] [Details]

Citations: Scopus - 10Web of Science - 11

Co-authors: Shastri MD; Stewart N; Eapen M; Peterson GM; Zaidi STR; Sohal SS; Patel RP

Tweet

2015Shastri MD, Stewart N, Horne J, Peterson GM, Gueven N, et al., 'In-vitro suppression of IL-6 and IL-8 release from human pulmonary epithelial cells by non-anticoagulant fraction of enoxaparin', PLoS One, 10, (5) Article e0126763. ISSN 1932-6203 (2015) [Refereed Article]

DOI: 10.1371/journal.pone.0126763 [eCite] [Details]

Citations: Scopus - 10Web of Science - 9

Co-authors: Shastri MD; Stewart N; Horne J; Peterson GM; Sohal SS; Patel RP

Tweet

2015Shastri MD, Stewart N, Horne J, Zaidi STR, Sohal SS, et al., 'Non-anticoagulant fractions of enoxaparin suppress inflammatory cytokine release from peripheral blood mononuclear cells of allergic asthmatic individuals', PLoS One, 10, (6) Article e0128803. ISSN 1932-6203 (2015) [Refereed Article]

DOI: 10.1371/journal.pone.0128803 [eCite] [Details]

Citations: Scopus - 13Web of Science - 11

Co-authors: Shastri MD; Stewart N; Horne J; Zaidi STR; Sohal SS; Peterson GM; Korner H; Patel RP

Tweet

2015Wanandy T, Guven N, Davies NW, Brown SGA, Wiese MD, 'Pilosulins: A review of the structure and mode of action of venom peptides from an Australian ant Myrmecia pilosula', Toxicon, 98 pp. 54-61. ISSN 0041-0101 (2015) [Refereed Article]

DOI: 10.1016/j.toxicon.2015.02.013 [eCite] [Details]

Citations: Scopus - 16Web of Science - 17

Co-authors: Wanandy T; Davies NW

Tweet

2015Yin X, Guven N, Dietis N, 'Opioids in depression: not quite there yet', UK Journal of Pharmaceutical and Biosciences, 3, (1) pp. 12-17. ISSN 2347-9442 (2015) [Refereed Article]

[eCite] [Details]

Co-authors: Yin X; Dietis N

Tweet

2014Alhusban AA, Gaudry AJ, Breadmore MC, Gueven N, Guijt RM, 'On-line sequential injection-capillary electrophoresis for near-real-time monitoring of extracellular lactate in cell culture flasks', Journal of Chromatography A, 1323 pp. 157-162. ISSN 0021-9673 (2014) [Refereed Article]

DOI: 10.1016/j.chroma.2013.11.006 [eCite] [Details]

Citations: Scopus - 20Web of Science - 18

Co-authors: Breadmore MC; Guijt RM

Tweet

2014Chhetri J, Jacobson G, Gueven N, 'Zebrafish - on the move towards ophthalmological research', Eye, 28 pp. 367-380. ISSN 0950-222X (2014) [Refereed Article]

DOI: 10.1038/eye.2014.19 [eCite] [Details]

Citations: Scopus - 45Web of Science - 46

Co-authors: Chhetri J; Jacobson G

Tweet

2014Paul A, Guven N, Dietis N, 'Opioid receptor-dependent modulation of insulin-release in pancreatic beta-cells', UK Journal of Pharmaceutical and Biosciences, 2, (6) pp. 22-31. ISSN 2347-9442 (2014) [Refereed Article]

[eCite] [Details]

Co-authors: Dietis N

Tweet

2014Lean QY, Patel RP, Stewart N, Sohal SS, Guven N, 'Identification of pro-and anti-proliferative oligosaccharides of heparins', Integrative Biology, 6, (1) pp. 90 - 99. ISSN 0974-2816 (2014) [Refereed Article]

DOI: 10.1039/c3ib40206a [eCite] [Details]

Citations: Scopus - 10Web of Science - 9

Co-authors: Lean QY; Patel RP; Stewart N; Sohal SS

Tweet

2013Shabala L, Walker EJ, Eklund A, Randall-Demllo S, Shabala S, et al., 'Exposure of colonic epithelial cells to oxidative and endoplasmic reticulum stress causes rapid potassium efflux and calcium influx', Cell Biochemistry and Function, 31, (7) pp. 603-611. ISSN 1099-0844 (2013) [Refereed Article]

DOI: 10.1002/cbf.2946 [eCite] [Details]

Citations: Scopus - 6Web of Science - 7

Co-authors: Shabala L; Walker EJ; Randall-Demllo S; Shabala S; Cook AL; Eri RD

Tweet

2012Erb M, Hoffmann-Enger B, Deppe H, Soedberdt M, Haefeli RH, et al., 'Features of idebenone and related short-chain quinones that rescue ATP levels under conditions of impaired mitochondrial complex I', PLoS One, 7, (4) Article e36153. ISSN 1932-6203 (2012) [Refereed Article]

DOI: 10.1371/journal.pone.0036153 [eCite] [Details]

Citations: Scopus - 47Web of Science - 42

Tweet

2012Heitz FD, Erb M, Anklin C, Robay D, Pernet V, et al., 'Idebenone protects against retinal damage and loss of vision in a mouse model of Leber's hereditary optic neuropathy', PLoS One, 7, (9) Article e45182. ISSN 1932-6203 (2012) [Refereed Article]

DOI: 10.1371/journal.pone.0045182 [eCite] [Details]

Citations: Scopus - 44Web of Science - 39

Tweet

2012Murad NAA, Cullen JK, McKenzie M, Ryan MT, Thorburn D, et al., 'Mitochondrial dysfunction in a novel form of autosomal recessive ataxia', Mitochondrion, 13, (3) pp. 235-245. ISSN 1872-8278 (2012) [Refereed Article]

DOI: 10.1016/j.mito.2012.11.006 [eCite] [Details]

Citations: Scopus - 3Web of Science - 4

Tweet

2011Dallmann R, Weyermann P, Anklin C, Boroff M, Bray-French K, et al., 'The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexia', Journal of Cachexia, Sarcopenia and Muscle, 2, (3) pp. 163-174. ISSN 2190-5991 (2011) [Refereed Article]

DOI: 10.1007/s13539-011-0039-1 [eCite] [Details]

Citations: Scopus - 28Web of Science - 27

Tweet

2011Gatei M, Jakob B, Chen P, Kijas AW, Becherel OJ, et al., 'ATM-Dependent Phosphorylation of RAD50 regulates DNA repair and cell cycle control', Journal of Biological Chemistry, 286, (36) pp. 31542-31556. ISSN 1083-351X (2011) [Refereed Article]

DOI: 10.1074/jbc.M111.258152 [eCite] [Details]

Citations: Scopus - 42Web of Science - 40

Tweet

2011Haefeli RH, Erb M, Gemperli AC, Robay D, Courdier Fruh I, et al., 'NQO1-Dependent Redox Cycling of Idebenone: effects on cellular Redox potential and energy levels', PLoS One, 6, (3) Article e17963. ISSN 1932-6203 (2011) [Refereed Article]

DOI: 10.1371/journal.pone.0017963 [eCite] [Details]

Citations: Scopus - 92Web of Science - 85

Tweet

2011Brown JA, Roberts TL, Richards R, Woods R, Birrell G, et al., 'A Novel Role for hSMG-1 in Stress Granule Formation', Molecular and Cellular Biology, 31, (2) pp. 4417 - 4429. ISSN 0270-7306 (2011) [Refereed Article]

DOI: 10.1128/MCB.05987-11 [eCite] [Details]

Citations: Scopus - 24Web of Science - 23

Tweet

2010Craig AL, Holcakova J, Finlan LE, Nekulova M, Hrstka R, et al., 'DeltaNp63 transcriptionally regulates ATM to control p53 Serine-15 phosphorylation', Molecular Cancer, 9, (195) pp. 1-13. ISSN 1476-4598 (2010) [Refereed Article]

DOI: 10.1186/1476-4598-9-195 [eCite] [Details]

Citations: Scopus - 26Web of Science - 24

Tweet

2010Morrow BJ, Keddie DJ, Gueven N, Lavin MF, Bottle SE, 'A novel profluorescent nitroxide as a sensitive probe for the cellular redox environment', Free Radical Biology & Medicine, 49, (1) pp. 67-76. ISSN 1873-4596 (2010) [Refereed Article]

DOI: 10.1016/j.freeradbiomed.2010.03.019 [eCite] [Details]

Citations: Scopus - 48Web of Science - 51

Tweet

2009Becherel OJ, Jakob B, Cherry AL, Guven N, Fusser M, et al., 'CK2 phosphorylation-dependent interaction between aprataxin and MDC1 in the DNA damage response', Nucleic Acids Research pp. 1-15. ISSN 1362-4962 (2009) [Refereed Article]

DOI: 10.1093/nar/gkp1149 [eCite] [Details]

Citations: Scopus - 32Web of Science - 31

Tweet

2007Gueven N, Becherel OJ, Howe O, Chen P, Haince J-F, et al., 'A novel form of ataxia oculomotor apraxia characterized by oxidative stress and apoptosis resistance', Cell Death and Differentiation, 14, (6) pp. 1149-1161. ISSN 1350-9047 (2007) [Refereed Article]

DOI: 10.1038/sj.cdd.4402116 [eCite] [Details]

Citations: Scopus - 12Web of Science - 10

Tweet

2007Suraweera A, Becherel OJ, Chen P, Rundle N, Woods R, et al., 'Senataxin, defective in ataxia oculomotor apraxia type 2, is involved in the defense against oxidative DNA damage', The Journal of Cell Biology, 177, (6) pp. 969-979. ISSN 1540-8140 (2007) [Refereed Article]

DOI: 10.1083/jcb.200701042 [eCite] [Details]

Citations: Scopus - 122Web of Science - 120

Tweet

2007Gueven N, Chen P, Nakamura J, Becherel OJ, Kijas AW, et al., 'A subgroup of spinocerebellar ataxias defective in DNA damage responses', Neuroscience: An International Journal, 145, (4) pp. 1418-1425. ISSN 0306-4522 (2007) [Refereed Article]

DOI: 10.1016/j.neuroscience.2006.12.010 [eCite] [Details]

Citations: Scopus - 44Web of Science - 41

Tweet

2006Gueven N, Luff J, Peng C, Hosokawa K, Bottle SE, et al., 'Dramatic extension of tumor latency and correction of neurobehavioral phenotype in Atm-mutant mice with a nitroxide antioxidant', Free Radical Biology and Medicine, 41, (6) pp. 992-1000. ISSN 0891-5849 (2006) [Refereed Article]

DOI: 10.1016/j.freeradbiomed.2006.06.018 [eCite] [Details]

Citations: Scopus - 60Web of Science - 56

Tweet

2006Lavin MF, Guven N, 'The complexity of p53 stabilization and activation', Cell Death and Differentiation, 13, (6) pp. 941-950. ISSN 1350-9047 (2006) [Refereed Article]

DOI: 10.1038/sj.cdd.4401925 [eCite] [Details]

Citations: Scopus - 461Web of Science - 445

Tweet

2005Truman J-P, Gueven N, Lavin M, Leibel S, Kolesnick R, et al., 'Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis', Journal of Biological Chemistry, 280, (24) pp. 23262-23272. ISSN 0021-9258 (2005) [Refereed Article]

DOI: 10.1074/jbc.M503701200 [eCite] [Details]

Citations: Scopus - 44Web of Science - 44

Tweet

2004Gueven N, Becherel OJ, Kijas AW, Chen P, Howe O, et al., 'Aprataxin, a novel protein that protects against genotoxic stress', Human Molecular Genetics, 13, (10) pp. 1081-1093. ISSN 0964-6906 (2004) [Refereed Article]

DOI: 10.1093/hmg/ddh122 [eCite] [Details]

Citations: Scopus - 128Web of Science - 120

Tweet

2004Lavin MF, Scott SP, Kozlov S, Gueven N, 'Analyzing the regulation and function of ATM', Methods in Molecular Biology, 281 pp. 163-178. ISSN 1064-3745 (2004) [Refereed Article]

[eCite] [Details]

Tweet

2003Glover D, Little JB, Lavin MF, Gueven N, 'Low dose ionizing radiation-induced activation of connexin 43 expression', International Journal of Radiation Biology, 79, (12) pp. 955-964. ISSN 0955-3002 (2003) [Refereed Article]

DOI: 10.1080/09553000310001632895 [eCite] [Details]

Citations: Scopus - 25Web of Science - 23

Tweet

2003Gueven N, Keating K, Fukao T, Loeffler H, Kondo N, et al., 'Site-directed mutagenesis of the ATM promoter: Consequences for response to proliferation and ionizing radiation', Genes, Chromosomes and Cancer, 38, (2) pp. 157-167. ISSN 1045-2257 (2003) [Refereed Article]

DOI: 10.1002/gcc.10261 [eCite] [Details]

Citations: Scopus - 26Web of Science - 26

Tweet

2003Kozlov S, Gueven N, Keating K, Ramsay J, Lavin MF, 'ATP activates ataxia-telangiectasia mutated (ATM) in vitro. Importance of autophosphorylation', Journal of Biological Chemistry, 278, (11) pp. 9309-9317. ISSN 0021-9258 (2003) [Refereed Article]

DOI: 10.1074/jbc.M300003200 [eCite] [Details]

Citations: Scopus - 68Web of Science - 65

Tweet

2002Beamish H, Kedar P, Kaneko H, Chen P, Fukao T, et al., 'Functional link between BLM defective in Bloom's syndrome and the ataxia-telangiectasia-mutated protein, ATM', Journal of Biological Chemistry, 277, (34) pp. 30515-30523. ISSN 0021-9258 (2002) [Refereed Article]

DOI: 10.1074/jbc.M203801200 [eCite] [Details]

Citations: Scopus - 96Web of Science - 93

Tweet

2001Dittmann KH, Gueven N, Mayer C, Rodemann HP, 'Characterization of the amino acids essential for the photo- and radioprotective effects of a Bowman-Birk protease inhibitor -derived nonapeptide', Protein Engineering, 14, (3) pp. 157-160. ISSN 0269-2139 (2001) [Refereed Article]

DOI: 10.1093/protein/14.3.157 [eCite] [Details]

Citations: Web of Science - 16

Tweet

2001Gueven N, Keating KE, Chen P, Fukao T, Khanna KK, et al., 'Epidermal Growth Factor Sensitizes Cells to Ionizing Radiation by Down-regulating Protein Mutated in Ataxia-Telangiectasia', Journal of Biological Chemistry, 276, (12) pp. 8884-8891. ISSN 0021-9258 (2001) [Refereed Article]

DOI: 10.1074/jbc.M006190200 [eCite] [Details]

Citations: Scopus - 45Web of Science - 40

Tweet

Chapter in Book

(1 outputs)
YearCitationAltmetrics
2016Lean QY, Gueven N, Eri RD, Peterson GM, Patel RP, 'Non-Anticoagulant Oligosaccharides of Enoxaparin Relieve Chemical-Induced Acute Colitis', Advances in Medicine and Biology, Nova Science Publishers, LV Berhardt (ed), United States, pp. 87-104. ISBN 978-1-63483-988-4 (2016) [Research Book Chapter]

[eCite] [Details]

Co-authors: Lean QY; Eri RD; Peterson GM; Patel RP

Tweet

Review

(9 outputs)
YearCitationAltmetrics
2015Buyse GM, Gueven N, McDonald CM, 'Idebenone as a Novel Therapeutic Approach for Duchenne Muscular Dystrophy', European Neurological Review, 10, (2) ISSN 1758-3837 (2015) [Review Several Works]

[eCite] [Details]

2015Yin X, Guven N, Dietis N, 'Opioids in Depression: Not Quite There Yet', UK Journal of Pharmaceutical and Biosciences, 3, (1) pp. 12-17. ISSN 2347-9442 (2015) [Substantial Review]

[eCite] [Details]

Co-authors: Yin X; Dietis N

2014Gueven N, 'Optic Neurodegeneration: Time to Act', Biology and Medicine, 1, (1) pp. 1-6. ISSN 0974-8369 (2014) [Substantial Review]

DOI: 10.4172/0974-8369.S1-001 [eCite] [Details]

Tweet

2013Gueven N, Faldu D, 'Therapeutic strategies for Leber's hereditary optic neuropathy: A current update', Intractable & Rare Diseases Research., 2, (4) pp. 130-135. ISSN 2186-3644 (2013) [Substantial Review]

[eCite] [Details]

Co-authors: Faldu D

2013Guven N, Faldu D, 'Idebenone treatment in Leber's hereditary optic neuropathy: rationale and efficacy', Expert opinion on orphan drugs, 2, (4) pp. 130-135. ISSN 2167-8707 (2013) [Substantial Review]

DOI: 10.1517/21678707.2013.772894 [eCite] [Details]

Citations: Scopus - 6Web of Science - 4

Co-authors: Faldu D

Tweet

2008Lavin MF, Gueven N, Grattan-Smith P, 'Defective responses to DNA single- and double-strand breaks in spinocerebellar ataxia', DNA Repair, 7 pp. 1061-1076. ISSN 1568-7864 (2008) [Substantial Review]

DOI: 10.1016/j.dnarep.2008.03.008 [eCite] [Details]

Citations: Scopus - 16Web of Science - 14

Tweet

2007Lavin MF, Guven N, Bottle S, Gatti RA, 'Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia', British Medical Bulletin, 81-82, (1) pp. 129-147. ISSN 0007-1420 (2007) [Substantial Review]

DOI: 10.1093/bmb/ldm012 [eCite] [Details]

Citations: Scopus - 104Web of Science - 85

Tweet

2005Lavin MF, Birrell G, Chen P, Kozlov S, Scott S, et al., 'ATM signaling and genomic stability in response to DNA damage', Mutation Research - D N Aging, 569, (1-2) pp. 123-32. ISSN 0921-8734 (2005) [Substantial Review]

[eCite] [Details]

Tweet

2004Lavin MF, Scott S, Gueven N, Kozlov S, Peng C, et al., 'Functional consequences of sequence alterations in the ATM gene', D N A Repair, 3, (8-9) pp. 1197-205. ISSN 1568-7864 (2004) [Review Several Works]

[eCite] [Details]

Tweet

Conference Publication

(4 outputs)
YearCitationAltmetrics
2017Cui H, Zhang A, Geraghty DP, Nott L, Guven N, et al., 'Tumour expression of copper transporters in colorectal cancer patients', Proceedings of APSA-ASCEPT 2017, 5-8 Dec 2017, Brisbane, pp. 538. (2017) [Conference Extract]

[eCite] [Details]

Co-authors: Geraghty DP

2016Cui H, Zhang A, Geraghty DP, Nott L, Guven N, et al., 'Targeting CTR1 to enhance the uptake and cytotoxicity of oxaliplatin in colorectal cancer cells', Proceedings of ASCEPT-APSA 2016, 27-30 Nov 2016, Melbourne, pp. 1. (2016) [Conference Extract]

[eCite] [Details]

Co-authors: Geraghty DP

2014Cui H, Zhang A, Geraghty DP, Nott L, Guven N, et al., 'Expression of copper transporters in colorectal cancer cells and its relation to oxaliplatin', Proceedings of ASCEPT-MPGPCR 2017, 7-11 Dec 2014, Melbourne, pp. 1. (2014) [Conference Extract]

[eCite] [Details]

Co-authors: Geraghty DP

2003Truman J-P, Gueven N, Lavin M, Leibel S, Kolesnick R, et al., 'Transcriptional down-regulation of Ataxia-Telangiectasia Mutated protein (ATM) radiosensitizes human prostate cancer cells', INIS Collection, 17-22 August 2003, Brisbane, Australia, pp. 100. (2003) [Refereed Conference Paper]

[eCite] [Details]

Tweet

Patent

(4 outputs)
YearCitationAltmetrics
2012Feurer A, Gueven N, Hoffman-Enger B, Erb M, Deppe H, et al., 'Benzoquinone Derivatives as Modulators of Mitochondrial Function' (2012) [Patent]

[eCite] [Details]

2012Feurer A, Hoffmann-Enger B, Deppe H, Soeberdt M, Gueven N, et al., 'Novel Benzoquinone Derivatives and Use Thereof as Modulators of Mitochondrial Function' (2012) [Patent]

[eCite] [Details]

2000Dittmann K, Guven N, Mayer C, Rodemann PH, 'Protection of cells in connection with treatment with chemical agents' (2000) [Patent]

[eCite] [Details]

1999Rodemann H, Dittmann K, Guven N, Mayer C, 'Peptide with radio protective effect' (1999) [Patent]

[eCite] [Details]

Grants & Funding

Assoc Prof Gueven's work is currently funded by charities, academic funding bodies and commercial entities: CIA on 4 pharmaceutical industry-related grants: 1x Department of Industry grant in 2014 (A$100k), 2x MarinovaPte research grants (~A$50k each) and 1x pilot grant with international pharmaceutical company (~A$50k). Multiple smaller grants from foundations and charities (A$10-20k per grant).

Funding Summary

Number of grants

24

Total funding

$2,873,138

Projects

Pre-clinical toxicity assessment to select drug development candidates against mitochondrial dysfunction (2020 - 2021)$144,300
Description
This application supports a valley of death project to generate the pre-clinical toxicity data that are required towards commercialisation of UTAS-derived novel drug candidates
Funding
National Foundation for Medical Research and Innovation ($144,300)
Scheme
Grant-Expression of Interest
Administered By
University of Tasmania
Research Team
Guven N; Smith JA; Ambrose M
Period
2020 - 2021
Pre-clinical toxicity assessment of test compounds (2019)$8,677
Description
This project will assess the short-term toxicity of 12 test compounds for Martha Jane Medical.
Funding
Martha Jane Medical ($8,677)
Scheme
Consultancy
Administered By
University of Tasmania
Research Team
Guven N; Jacobson GA
Year
2019
HDAC6 inhibition to rescue axon degeneration in ALS (2019 - 2022)$997,046
Description
We will test an HDAC6 inhibitor in models of ALS. We will investigate the HDA6 inhibitor activity of novel compounds
Funding
FightMND ($997,046)
Scheme
Grant - Drug Development Grant
Administered By
University of Tasmania
Research Team
King AE; Cook AL; Guven N; Van Den Bosch L; Dickson TC; Blizzard C; Vickers JC; Smith JA; Alty JE; Leung JY; Perry SE
Period
2019 - 2022
Can idebenone be used to reduce severity of stroke? (2019)$9,962
Description
There are no drugs that improve the outcomes following a stroke. We have recently identified idebenone as a neuroprotective agent during times of energy stress. This pilot project will investigate whether idebenone can be used to reduce the severity of stroke in a pre-clinical animal model.
Funding
Royal Hobart Hospital Research Foundation ($9,962)
Scheme
Grant-Incubator
Administered By
University of Tasmania
Research Team
Premilovac D; Sutherland BA; Howells DW; Guven N; Castley H
Year
2019
Isolation and synthesis of potential new therapeutic agents from Hemp (Cannabis sativa) and their biological evaluation (2018 - 2021)$105,000
Description
Cannabis and cannabis extracts have been reported to have beneficial applications to many indications including the management of seizures, pain, cancer and appetite amongst others. One problem has been the illicit nature of the material which results in lack of control of the dose and chemical profile of material which can be due to different plant varieties, growing conditions, extraction preparation and mode of delivery. This project aims to adopt a drug discovery approach to provide solid evidence for the effect of different cannabinoids by isolating the individual components for thorough evaluation of any therapeutical applications. In this way, clear dose dependant activity can be studied and protocols for the prescription of cannabinoids can be developed that are in-line with modern pharmaceutical procedures. This will also be the start point for the development of novel semi-synthetic cannabinoids that will allow us to develop structure activity relationships for different indications. This potentially extends the scope of the medicinal cannabis industry to be a raw material for the synthesis of active non-natural derivates similar to the semi-synthetic opiates.
Funding
Martha Jane Medical ($105,000)
Scheme
Contract Research
Administered By
University of Tasmania
Research Team
Smith JA; Jacobson GA; Guven N; Bissember AC
Period
2018 - 2021
Investigation into an overlooked pathway towards anti-cancer immunity. Inhibitory motifs in the extracellular domains of immune checkpoint molecules (2017)$36,155
Description
Checkpoint molecule blockade immunotherapy (e.g. PD-1 monoclonal antibody) has achieved unprecedented success in treating several types of cancer, and ITIM and ITSM signalling play a key role in these treatment approaches. The cancer immunotherapy market reached $16.9 billion in 2015 and is expected to grow to $75 billion by 2022 (GBI 2016). This has greatly improved patient outcomes, but the cost to a single patient can exceed $100,000. The research proposed here has the potential to discover many new drug targets. Importantly, the targets are short peptide sequences, which open the door to using small molecule compounds instead that can be produced and formulated at a significantly lower cost than protein-based therapies. This will benefit cancer patients by reducing the cost for treatment and simultaneously help UTAS enter the rapidly expanding cancer immunotherapy market.
Funding
University of Tasmania Foundation Inc ($36,155)
Scheme
Grant-Cancer Research
Administered By
University of Tasmania
Research Team
Flies AS; Guven N; Blackburn NR; Lyons AB
Year
2017
Anti-inflammatory efficacy of Marinovas Fucoidan & interactions with microbiota (2016)$100,000
Description
Industry interaction to develop Marinovas fucoidan extracts for gut health
Funding
Department of Industry, Innovation and Science ($50,000); Marinova Pty Ltd ($50,000)
Scheme
Contract Research
Administered By
University of Tasmania
Research Team
Guven N; Eri RD; Ahuja KDK; Ball MJ; Ambrose M; Roddam LF; Zosky GR
Year
2016
Short chain quinones against diabetic retinopathy (2016 - 2019)$75,174
Description
We will test novel short chain quinones against idebenone and related compounds in a rat model of diabetic retinopathy.
Funding
Santhera Pharmaceuticals Holding AG ($75,174)
Scheme
Contract Research
Administered By
University of Tasmania
Research Team
Guven N; Premilovac D; Foa LC
Period
2016 - 2019
Generating and characterizing a reliable rodent model type 2 diabetes (2016)$14,673
Funding
University of Tasmania ($14,673)
Scheme
Grant-Research Enhancement (REGS)
Administered By
University of Tasmania
Research Team
Premilovac D; Foa LC; Taylor BVM; Guven N
Year
2016
Fucoidan and cell cycle regulation (2015 - 2016)$54,917
Description
This project involves industry interaction to develop Marinova's fucoidan extract against cancer.
Funding
Marinova Pty Ltd ($54,917)
Scheme
Contract Research
Administered By
University of Tasmania
Research Team
Guven N; Dietis ND; Davis E
Period
2015 - 2016
Fucoidan and stem cell mobilisation (2015)$27,048
Description
Industry interaction to test if Marinova's fucoidan extracts mobilise stem cells.
Funding
Marinova Pty Ltd ($27,048)
Scheme
Clinical Trial
Administered By
University of Tasmania
Research Team
Guven N; Eri RD; Ahuja KDK; Patel RP
Year
2015
Fucoidan and gut health (2015)$100,000
Description
This project represents industry interaction to develop Marinovas fucoidan extract for gut health.
Funding
Department of Industry and Science ($50,000)
Scheme
Grant
Administered By
University of Tasmania
Research Team
Guven N; Davis E; Eri RD; Patel RP
Year
2015
Bi-functional opioids as a novel cancer treatment (2015)$6,567
Description
The aim of our study is to assess the anticancer effect of our 10 novel opioid drugs in six different intestinal cancer cell lines and compare them with oxaliplatin and irinotecan. The particular objectives of the study are:1. To evaluate the effect of our novel drugs on intestinal cancer cell viability, growth, proliferation and ability to form colonies.2. To explore the molecular mechanisms of the anticancer activity of our novel drugs.
Funding
Cancer Council of Tasmania ($6,567)
Scheme
Grant-Cancer Research
Administered By
University of Tasmania
Research Team
Dietis ND; Liu JJ; Holloway AF; Guven N
Year
2015
Novel short-chain quinones against inherited blindness (2015)$6,900
Description
Sufficient cellular energy production is essential for normal vision, which is exemplified by Lebers Hereditary Optic Neuropathy (LHON). This disorder is a devastating disease that affects predominantly young men in their 20s to 30s. Affected individuals typically have normal vision, before in their 20s they irreversibly lose their vision. Currently, there is no treatment on the market to prevent or restore vision loss. However, several clinical trials in LHON and other mitochondrial optic neuropathy patients support a limited therapeutic benefit of short-chain quinone compounds. Based on previous in-depth experience with this class of compounds in vitro and in-vivo acquired in commercial and academic laboratories, the project proposes to discover and characterize novel quinone compounds with improved activity. This project is based on a rational medicinal-chemistry optimization program to improve the activity of known molecules and to provide a safe and cost-effective prevention and therapy option for optic neuropathy patients.
Funding
Rebecca L Cooper Medical Research Foundation ($6,900)
Scheme
Grant
Administered By
University of Tasmania
Research Team
Guven N
Year
2015
Non anticoagulant molecules of heparin for the management of ulcerative colitis (2015)$15,000
Description
This project aims to achieve the identification and evaluation of non-anticoagulant molecules of heparin that are responsible for the observed beneficial effects of heparin in patients with ulcerative colitis as well as to compare potential biomarkers in a preclinical muse model with ulcerative colitis patients.
Funding
Royal Hobart Hospital Research Foundation ($15,000)
Scheme
Grant-Clinical Research
Administered By
University of Tasmania
Research Team
Patel RP; Guven N; Eri RD; Bhatia R
Year
2015
Development of a therapeutic agent for a chemotherapy-induced neuropathy (2015)$21,739
Description
Chemotherapy-induced neuropathy (CIN) is a dose-limiting side effect of chemotherapy treatment, causing irreversible disability in 40% of cancer survivors. CIN results from the loss or damage of neurons during chemotherapy. We have compelling evidence that the protein metallothionein promotes regeneration of peripheral nerves, and examine its therapeutic use in CIN.This project will create new knowledge in the area of chemotherapy induced neuropathy, and establish the suitability of trophic agents as disease-modifying agents for chemotherapy-induced neuropathy.
Funding
Royal Hobart Hospital Research Foundation ($21,739)
Scheme
Grant-Clinical Research
Administered By
University of Tasmania
Research Team
Taylor BVM; Landowski LM; West AK; Vickers JC; Foa LC; Guven N
Year
2015
Comparison of idebenone and CoQ10 (2014)$3,830
Description
This project is a literature overview on the comparison of the two benzoquinones idebenone and CoQ10, with regards to biological and therapeutic activity.
Funding
Santhera Pharmaceuticals Holding AG ($3,830)
Scheme
Consultancy
Administered By
University of Tasmania
Research Team
Guven N
Year
2014
Fucoidan extract in the treatment of ulcerative colitis in an animal model (2013)$2,810
Description
Brown algal extracts, in particular those containing fucoidan have been shown to have potential applications in a number of health indications such as prediabetes, immunomodulation, cardiovascular disease, inflammation and gut health. With advances in technology, fucoidan extracts from brown seaweed can now be produced successfully on a commercial scale. These types of extracts are beginning to become more prevalent as ingredients in western dietary supplement markets. However, for the extracts to successfully enter this market, efficacy, safety and provenance must be proven to help gain acceptance. With this in mind, the objectives of this project include the following: to establish the efficacy of high purity fucoidan extract from Fucusvesiculosus in the treatment of ulcerative colitis in an animal model; and to compare the efficacy of the routes of administration of Fucusvesiculosus fucoidan in treating ulcerative colitis with particular reference to oral and intra-peritoneal dosages.
Funding
Marinova Pty Ltd ($2,810)
Scheme
Contract Research
Administered By
University of Tasmania
Research Team
Peterson GM; Guven N; Patel RP
Year
2013
Neuroprotective function of novel short chain-quinones (2013)$9,090
Description
Most eye disorders are associated with mitochondrial dysfunction. Based on the mitochondria-protective drug idebenone, we will synthesize novel, improved neuroprotective compounds. These compounds will be tested in a microfluidics cell culture model of mechanical stress-induced neuro-degeneration to identify new treatments strategies against retinal degeneration.
Funding
Royal Hobart Hospital Research Foundation ($9,090)
Scheme
Grant-Research
Administered By
University of Tasmania
Research Team
McCartney PJ; Guven N; Guijt RM; Smith JA
Year
2013
Protection against spontaneous and radiation-induced intestinal cancer by the novel antioxidant CTMIO (2008)$160,000
Funding
The Cancer Council, Queensland ($160,000)
Scheme
Project
Administered By
Queensland Institute of Medical Research
Research Team
Lavin MF; Gueven N
Year
2008
Use of the novel nitroxide antioxidant CTMIO in a GAA repeat mouse model of Friedreichs Ataxia (2007)$100,000
Funding
National Ataxia Foundation (NAF) / Friedreich’s Ataxia Research Alliance (FARA), USA ($100,000)
Scheme
Kyle Bryant Translational Research Award
Administered By
Queensland Institute of Medical Research
Research Team
Gueven N; Pook M
Year
2007
Senataxin, a novel protein involved in the DNA damage response (2007 - 2009)$466,500
Funding
National Health and Medical Research Council ($466,500)
Scheme
Project
Administered By
Queensland Institute of Medical Research
Research Team
Lavin MF; Gueven N; Becherel O
Period
2007 - 2009
Functional Role of Aprataxin: Mutated in Ataxia with Oculomotor Apraxia (2005 - 2007)$267,750
Funding
National Health and Medical Research Council ($267,750)
Scheme
Project
Administered By
Queensland Institute of Medical Research
Research Team
Lavin MF; Gueven N
Period
2005 - 2007
Role of ATX/hSMG1 protein in responding to DNA damage and maintaining genome stability (2004 - 2005)$140,000
Funding
Queensland Cancer Fund ($140,000)
Scheme
Project
Administered By
Queensland Institute of Medical Research
Research Team
Lavin MF; Gueven N
Period
2004 - 2005

Research Supervision

Nuri supervises a number of PhD candidates at the University of Tasmania. Recently, one of his students was invited to present her results at a prestigious Gordon Conference in Italy and another one generated the data that resulted in a patent application. He also trained numerous technical staff and actively mentors the junior colleagues within Pharmacy. He is involved in undergraduate teaching and is a regular contributor to practicals and tutorials for Pharmacy students. The quality and impact of his undergraduate lectures has been acknowledged by both the course co-ordinators and students.

Current

8

Completed

10

Current

DegreeTitleCommenced
PhDDissecting the Pharmaceutical and Immunological Aspects of Myrmecia pilosula (Jack Jumper) Ant Venom Immunotherapy2012
PhDMitochondrial Therapy against Diabetic Retinopathy2015
PhDTargeting Wnt Signaling Pathway in the Treatment of Colorectal Cancer2016
PhDDrug-Driving in Tasmania: Acute and Chronic Effects of Quetiapine and Opioids on Driving Ability2016
PhDEvaluating theTherapeutic Potential of Novel Idebenone Formulations Following Experimental Traumatic Brain Injury2017
PhDSynthesis and Evaluation of New Compounds for Drug Discovery2017
PhDIdentification and Characterisation of Novel Therapeutic Targets for the Control of Brain Cancers2019
PhDCellular and Molecular Events in Progression of Medulloblastoma2019

Completed

DegreeTitleCompleted
PhDInvestigation on the Utilization of Beneficial Microbes in Modulating the Gut Microbiota and Metabolic Profiles in Ageing
Candidate: Ravichandra Vemuri
2019
PhDNovel Short-Chain Quinones Against Mitochondrial Dysfunction
Candidate: Monila Nadikudi
2019
PhDThe Mutagenic Activity of Oxazolopyridine Compounds
Candidate: Hsien Hooi Lee
2018
PhDThe Role of Copper Transporters in In Vitro Cytotoxicity of Oxaliplatin and Their Expression in Colorectal Cancer
Candidate: Haigang Cui
2018
PhDStrategies to Reduce the Impact of Opioid-Induced Adverse Effects
Candidate: Alok Kumar Paul
2018
PhDPharmacological Modulation of Mood, Behaviour and Cognition
Candidate: Xin Yin
2018
PhDSynthesis of New Derivatives Targeting Mitochondrial Dysfunction
Candidate: Krystel Lee Woolley
2018
PhDTowards Understanding the Mechanism of Clioquinol Neurotoxicity
Candidate: Jamuna Chhetri
2017
PhDBioprocess Monitoring Using Sequential Injection Capillary Electrophoresis
Candidate: Ala Abdul Kareem Ahmad Alhusban
2016
PhDHeparins and Fucoidans: Future therapeutic options for ulcerative colitis
Candidate: Qi Ying Lean
2016